<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00702494</url>
  </required_header>
  <id_info>
    <org_study_id>07-TB-403-02</org_study_id>
    <secondary_id>EUDRACT No: 2008-001345-25</secondary_id>
    <nct_id>NCT00702494</nct_id>
  </id_info>
  <brief_title>Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours</brief_title>
  <official_title>An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrombogenics NV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioInvent International AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody
      binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding,
      growth of tumor vessels are inhibited and tumor growth prevented.

      In this study we are investigating the tolerability and safety of TB-403 in patients with
      solid tumors who receives multiple intravenous doses of TB-403.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of an anti-PlGF antibody</measure>
    <time_frame>85 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine multiple dose IV pharmacokinetics</measure>
    <time_frame>85 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple IV doses of TB-403, an antibody directed against PlGF</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TB-403</intervention_name>
    <description>Multiple IV</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed malignity

          -  Measurable disease

          -  Performance status 1 or less (ECOG)

        Exclusion Criteria:

          -  Acute illness or infection

          -  Concurrent second malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Lassen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lena Winstedt, PhD</last_name>
    <role>Study Director</role>
    <affiliation>BioInvent International AB</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorthe Nielsen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital, Herlev, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Onkologisk Klinik 5072 Finsencentret Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologisk Afdeling 54B1 Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>DK-2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2008</study_first_submitted>
  <study_first_submitted_qc>June 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2008</study_first_posted>
  <last_update_submitted>December 3, 2009</last_update_submitted>
  <last_update_submitted_qc>December 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Steven Glazer, Senior Vice President, Development</name_title>
    <organization>Bioinvent International AB</organization>
  </responsible_party>
  <keyword>placental growth factor</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Phase I</keyword>
  <keyword>solid tumors</keyword>
  <keyword>Patients with solid tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

